This Viewpoint addresses the dual domains of psychedelic experience—neurobiological changes and subjective experience—and argues for rigorous investigation of both domains.
There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic outcomes in patients with depression or...